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Abstract.
BACKGROUND: Few studies have reported on long-term harms caused by ADHD drugs but they are known to impair
growth.
OBJECTIVE: To assess whether ADHD drugs impair reproduction in mammals.
METHODS: Systematic review of reproduction in studies of animals treated with ADHD drugs.
DATA SOURCES: PubMed, Biosis and EMBASE.
RESULTS: We included 17 studies. The studies were generally of poor quality or poorly reported. Two studies reported the
use of one of three advised randomisation methods. Fifteen studies used placebo which suggested blinding. On clonidine,
the ability to produce offspring was reduced for male rats, which approached two females each. In one study, 10 treated rats
produced no offspring while all four controls did. In another study, 10 treated rats impregnated nine females while 10 controls
impregnated 16. On methylphenidate, vaginal opening was delayed in two studies (in one, the mean difference was 4.0 days,
95% CI 2.5 to 5.6, and number of estrous cycles was halved; in the other, the minimum delay was 6 days), while in two other
studies no difference occurred. Generally, the impairments improved after a drug-free period and were less pronounced when
treatment started later in life.
CONCLUSION: ADHD drugs impair the reproduction in animals.
Keywords: Animals, ADHD, reproduction, methylphenidate, clonidine, fertility
1. Background
Little is known about long-term outcomes of ADHD drugs but they do not appear to be positive. The
largest study, the Multimodal Treatment Study (MTA), randomised 579 children to methylphenidate,
behavioural therapy, both, or routine community care [1, 2]. There were no clinically important effects
of methylphenidate after 14 months, or after three and eight years of follow-up [3–5]. Similarly, a large
cohort study that investigated overall functioning at six years of follow-up found that psychostimulants
did not lower ADHD symptom severity [6].
The randomised trials included in a recent Cochrane review underreported the harms of
methylphenidate in children [7]. Only 5% of the included trials reported on serious adverse events,
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while 14% reported non-serious adverse events; these were more common with methylphenidate than
with placebo (risk ratio 1.29; 95% confidence interval 1.10 to 1.51).
Methylphenidate is a norepinephrine-dopamine reuptake inhibitor that acts predominantly through
the dopamine system. There are concerns that treating children with stimulants may cause irreversible
brain damage [8], as well as damages to the neuroendocrine system during development [9], because
dopamine acts both as a neurotransmitter and a regulator of hormonal pathways [10].
Exposure to ADHD drugs stunts growth [11] and may possibly also impair the development of the
reproductive system. A case has been described where a boy before being put on drugs experienced
sexual hyperactivity and was diagnosed with precocious puberty [12]. He was treated off-label with
methylphenidate from age five, which caused a decrease in both aggression and hypersexuality. Another
case report is about a boy treated with methylphenidate for 17 years since childhood who experienced
delayed puberty; at age 20 he had underdeveloped genitalia, lack of libido and also erectile dysfunction
[13]. A study that investigated pubertal development in 65 boys on stimulant medication for at least
three years found a slower rate of physical development of the genitals during puberty compared to
174 controls [14]. In contrast, some studies and case reports have shown increased sexual activity and
priapism with methylphenidate [15, 16].
When methylphenidate was administered to young rats, corresponding in age to prepubertal children,
it resulted in altered levels of dopamine transporters that persisted into adulthood, long after termination
of treatment [9]. Another study in rats found that methylphenidate impaired spermatogenesis after
eleven weeks of treatment, which indicated that the drug might reduce male fertility [17].
A large report from 2005 reviewed the reproductive and developmental effects of methylphenidate
[18]. There were no data on humans and for animals, the working group felt it did not have sufficient
data to give advice, although they mentioned two studies with rodents demonstrating reduced sperm
motility and altered estrous cycling, respectively, and one study reporting no differences.
We decided to do a systematic review of animal studies to assess the impact of ADHD drugs on the
development of the reproductive system.
2. Aim
To assess whether drugs approved for ADHD cause abnormal development of the reproductive
system in animals.
3. Methods
3.1. Search strategy
Searches were performed in PubMed, Biosis and Embase, using MeSH terms or equivalents, for
the eight most sold ADHD drugs in 2012 as reported by the US Food and Drug Administration:
atomoxetine, clonidine, dexmethylphenidate, dextroamphetamine, guanfacine, lisdexamphetamine,
methylphenidate and amphetamine [19]. The search strategies are available in Appendix A. We also
checked the references in a previous review for eligible studies [18].
We contacted the authors when data were unclear or not reported for papers published in 2000 or
later.
3.2. Eligibility criteria and data extraction
We included controlled studies of ADHD drugs given postnatally to healthy mammals, which were
not primed by drugs or had been operated upon, if they had data on one or more of the following
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outcomes: morphology, motility of spermatozoa, ejaculation, cell counts, cycles, pregnancies and
births (impregnations, resorptions, number of stillborns, number of liveborns with malformations).
We did not assess the reproductive organs of offspring from dams treated during pregnancy.
One observer screened all records and a second observer screened all included records and a random
sample of 15 excluded records (no disagreements). Potentially eligible articles were collected and read
in full. References of eligible articles were scanned to locate further studies. Data were recorded in
Excel. One investigator carried out data extraction and a second investigator checked the extracted
data. Disagreements were resolved by consensus.
We extracted data according to published guidelines [20–23]: animals (species, strain, age, sex),
study design (randomisation, blinding, drug intervention, group sizes, dose, route of administra-
tion, length of treatment and of follow-up), selective reporting within studies and relevant outcome
measures.
3.3. Quantitative data synthesis
Meta-analyses were performed with Review Manager using data from the end of the intervention
and, if available, the last time point after a drug free follow-up period. If the test had been carried out
on several consecutive days, we only used the results from the first day.
If more than one drug had been tested in the same trial, we split the control groups accordingly to
avoid double counting. For studies with several drug doses, dose groups were pooled [24]. Data from
animals kept group-housed or isolated were pooled. Missing standard deviations were calculated or
estimated by standard methods [24], e.g. imputation from SEs or p-values.
Risk of bias was assessed according to SYRCLE [20, 24]. For animal studies, the SYRCLE risk
of bias tool recommends assessment of three categories of randomisation: randomisation of animals
to intervention or control groups; random housing to prevent behavioural differences between groups
introduced through differences in light intensity and temperature; and random outcome assessments
to prevent influence on results from diurnal variation [20].
3.4. Statistical methods
We used a random effects model. For binary data, risk ratios were reported. For meta-analyses of
continuous data and ranking scale data, the mean difference or the standardised mean difference were
calculated.
The basic assumption was that the healthy control animals showed normal development and
behaviour. As there were differences in the direction of the scales and outcomes, we multiplied some
of the outcome values by –1 to ensure that values to the right in the graphs always meant an effect in
favour of placebo or no treatment.
Proportions were compared with Fisher’s exact test.
3.5. Amendment to the protocol
As our data extraction resulted in a large amount of outcomes, we decided to focus on the outcomes
directly related to the ability to reproduce (motility of spermatozoa, ejaculations, cycles, pregnancies
and labour) and not the indirect or surrogate ones (cell counts, morphology).
We had planned sensitivity analyses but there was too little data to allow these.
Our protocol is in Appendix B.
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4. Results
We identified 518 unique records and excluded 461 based on title or abstract for one or more of
these reasons: not an ADHD drug, primed animals, irrelevant outcomes, in vitro studies or otherwise
not an animal study, or polytherapeutic interventions. We also excluded a study in Japanese [25].
Full text screening of the remaining 57 articles led to inclusion of 17 studies (see flow chart in
Appendix C).
4.1. Study characteristics
All 17 included studies were controlled and they were published between 1975 and 2016 (Table 1).
Thirteen studies were conducted in rats [17, 26–37]; two in mice [38, 39]; two in dogs [40, 41]; and one
rat study also included rabbits [36]. Median number of animals per study was 30 for the intervention
groups (range 4–100) and 17 for the control groups (range 4–41) for the 16 studies where information
was given.
Methylphenidate was used in nine studies, clonidine in seven and amphetamine in one. The median
intervention period was 28 days (range 1–90) and there were follow-up data for eight studies (median
18 days, range 1–63 days) [17, 27, 31, 33, 34, 36, 37, 41].
4.2. Risk of bias
The studies were generally of poor quality or poorly reported. Two studies did not use a placebo
[17, 26]. Fifteen studies were placebo-controlled, which suggests that they were also blinded. Only
one study [32], however, described in detail the blinding of the observers. According to the SYRCLE
guidelines [21], we considered blinding of caregivers and personnel as unclear or at high risk of bias
either because blinding was not mentioned or because the control groups did not receive placebo.
Randomisation to either intervention or control was mentioned in two trials [32, 41], but the method
was not described. Randomisation of housing and outcome assessments was not described in any of
the reports.
Three studies reported the outcomes selectively [26–28] whereas the remaining studies reported all
described outcomes. Five studies reported on mortality or adverse events of the drugs [17, 26, 34–36].
Nine reports mentioned that funding was provided by public institutions [17, 28–33, 37, 39] and the
authors of seven studies declared that they had no conflicts of interest.
In total, there were 12 studies eligible for meta-analysis; for the five remaining studies there were
missing data we could not obtain [26, 28, 34, 40] or the data were not independent [32].
4.3. Amphetamine
One study tested amphetamine on 95 mice compared to 24 controls; there were no differences
between the groups for number of ejaculations and ejaculation latency [39], see Fig. 1.
4.4. Clonidine
In one study [34], ten male clonidine-treated rats were tested for their ability to impregnate two
female rats each, compared to four untreated rats. All control rats impregnated two dams each, but the
treated rats failed to impregnate any of the female rats (P = 0.001 for difference between 4 of 4 and 0 of
10, our calculation). The rats were either unable to ejaculate (no sperm present in the vagina); or they
were sterile (no embryos present in womb at day 12 after the encounters); or they did not approach
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Fig. 1. Studies or subgroups – as listed by first author, publication year, short for the drug used, species, and FU if feasible –
showing ejaculations as standardised mean difference and 95% confidence intervals. Total is number of animals per group.
FU – follow-up, CLO – clonidine, AMPH – amphetamine, MPH – methylphenidate.
Fig. 2. Studies or subgroups – as listed by first author, publication year, short for the drug used, species, and FU if feasible –
showing data for spermatozoa as mean difference with 95% confidence intervals. Total is number of animals per group. FU
– follow-up, CLO – clonidine, MPH – methylphenidate.
the females (four cases). After a drug-free period of seven days, the treated male rats approached one
female again; seven of 10 animals were able to impregnate one female rat each compared to all four
control rats (P = 0.51, our calculation).
Another study found a similar effect [32]. Ten male rats treated with clonidine impregnated nine of
20 females, and ten control rats impregnated 16 of 20 females (P = 0.05 when disregarding that the
observations were not independent, as each male rat approached two females).
For one study with four dogs in each group, the ejaculation score (from 0 to 3), elicited by manual
stimulation by the experimenter one hour after a clonidine injection, was lower for treated dogs than
for controls [40]. All control dogs scored the maximum of 3 (ejaculation happened), while the mean
score for treated dogs was only 0.65 (SD 0.78) (P = 0.004, sign test of 0 vs 8, our calculation), see
Fig. 1.
Sperm transit time through the epididymis, which is the time it takes the sperm to become mature,
was significantly shorter in clonidine-treated rats than in controls (mean difference 2.1 days; 1.2 to
3.0; 6 treated vs 6 controls) [30], see Fig. 2.
We could not extract any meaningful data from another clonidine study because the number of rats
was not mentioned in the results section [26]. Half of 40 female rats treated with clonidine before and
during pregnancy were sterile but the results for the control group were not mentioned [26].
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4.5. Methylphenidate
A rat study found that vaginal patency was delayed when treatment started five days after birth (mean
difference 4.0 days; 2.5 to 5.6; 13 treated vs 11 controls) [31]. When treatment started 21 days after
birth, there was an insignificant delay (mean difference 3.1; –1.6 to 7.8; 9 treated animals vs 9 controls).
Another study with ten rats in each group found vaginal opening to be delayed for a minimum of six
days; vaginal opening remained poor throughout the entire 30-day study for six of the treated rats [28].
In contrast, two other studies, with 42 vs 28 [37] and 30 vs 10 rats [27], found no difference between
groups for age at vaginal opening.
Female rats showed abnormal estrous cycling (counted as number of days per cycle) when the
treatment started at postnatal day 21; the number of cycles was halved for treated rats (mean difference
3.1 days; 2.4 to 3.8; 9 treated rats vs 9 controls) [31]. After a 30-day drug-free period, estrous cycling
did not normalise for rats starting treatment early, at postnatal day 5 (mean difference 2.9; 1.7 to 4.2;
13 treated vs 11 controls), but it did normalise for rats that started treatment at postnatal day 21 (9 rats
per group).
Another study, in which treatment started at postnatal day 21, found no differences in estrous cycling
patterns (42 vs 28 rats) after 40 days of treatment and a 15-day drug-free follow-up [37], whereas a study,
in which treatment started at postnatal day 28 and continued for four weeks, with 10 rats per group,
reported that all the treated rats showed impaired estrous cycling [28].
Fertility rates were 42% for six methylphenidate-treated mice approaching 3 female mice each and
95% for three untreated animals (counted as number of embryos per corpora lutea) [38]. On average,
the gestation period was significantly longer in 100 treated rats compared to 24 control rats, but the
difference was only half a day [35]. The results are shown in Figs. 3 and 4.
For the pregnancies that led to successful deliveries, no differences were seen in number of stillborns,
offspring or exterior malformations [27, 35, 36], see Fig. 5.
Abnormal tail development occurred in 2.0% of sperms in 29 methylphenidate-treated rats and in
1.2% of 15 controls (mean difference 0.9%; 0.4 to 1.4) [33]. Forty days after end of treatment, 79%
vs 85% of the sperms were viable (mean difference 6%; 1 to 11), see Fig. 2. There was no difference
in number of ejaculations [33], see Fig. 1.
Fig. 3. Studies or subgroups – as listed by first author, publication year, short for the drug used, species, and FU if feasible
– showing pregnancy and labour outcomes as standardised mean difference with 95% confidence intervals. Total is number
of animals per group. FU – follow-up, MPH – methylphenidate.
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Fig. 4. Studies or subgroups – as listed by first author, publication year, short for the drug used, species, and FU if feasible
– showing reproductive ability as mean difference with 95% confidence intervals. Total is number of animals per group. FU
– follow-up, MPH – methylphenidate.
Fig. 5. Studies or subgroups – as listed by first author, publication year, short for the drug used, species, and FU if feasible
– showing binary outcomes as the risk ratio with 95% confidence intervals. Total is number of animals per group. FU –
follow-up, MPH – methylphenidate.
In a study of 15 vs 8 rats receiving methylphenidate or placebo for 11 weeks, there were only trivial
differences between motility and viability of the sperms [17], see Fig. 2.
5. Discussion
We found that clonidine and methylphenidate impaired reproduction in animals. These harms might
be reversible if the treatment is not started early in life. We did not find an effect on number of stillborns,
number of offspring or visible malformations. However, one of our included studies assessed the
newborns’ skeletons and found that the pelvis, pubis and sternum were incompletely ossified compared
to controls [36].
5.1. Strengths and limitations
It was a strength that nine of the 17 studies were publicly funded and that we only included studies
where the animals had not been primed in any way, as priming might make the results difficult to
interpret.
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Fifteen of the 17 studies were placebo-controlled. This usually implies blinding of the observers, but
this information was only given in detail for one study. No studies mentioned whether the caregivers
and other personnel involved in the study were blinded, but in animal studies, the caregiver and the
observer are sometimes the same person. This may mean that use of a placebo has not necessarily led
to blinding since there could be differences in, for example, the colour of the food.
No studies adequately described that the animals were randomised in the three ways advised by
SYRCLE [20]. For our study, the possible lack of random outcome assessments may have had little
influence, as few of our outcomes were subjective or addressed behavior, which could vary over the day.
The possible lack of random housing could have influenced the neuroendocrine system and thereby
the results.
Eleven studies were published before the introduction of the ARRIVE guidelines in 2010 [42].
The guidelines have not yet been sufficiently implemented, as researchers, journal editors and ethical
committees do not focus enough on the importance of blinding and randomisation for minimizing bias
[43]. Animal research is often the basis for studies in humans and they therefore need to be performed
with the same rigour as randomised trials in patients in order to reduce research waste because of
false leads.
The studies were rather small and highly heterogeneous, using different species, strains, age at start
of intervention, treatment periods, route of administration, test settings and outcome measures. In the
two studies of methylphenidate that did not find differences between treated groups for age at vaginal
opening, the drug was given as oral gavage [27, 37], whereas it was administered subcutaneously in
the two studies that did find a difference [28, 31]. The significant findings might be due to the animals
receiving a higher dose. Delayed vaginal opening is similar to a late entering into puberty in humans
[44].
It can be discussed to which extent the studies reflected clinical use of ADHD drugs [45]. In some
studies, the treatment was started shortly after birth, which does not happen in humans. On the other
hand, the length of treatment was short compared to the clinical setting. The results we found might
therefore have both over- and underestimated the problems with these drugs.
5.2. Comparison with data from humans
Data on reproductive parameters in humans when treated with ADHD drugs is sparse [12–16]
and we have not found any long-term data that could elucidate whether ADHD drugs irreversibly
impair the reproductive system. Children are being treated with ADHD drugs at an ever earlier age
and sometimes continue with the drugs for decades although these long-term treatments are based
on short-term studies. In a large Cochrane review of methylphenidate in children, the median length
of treatment for parallel group trials was only 49 days [7]. This review found that all trials were of
high risk of bias [7], and only 5% of trials reported on serious adverse events while 14% reported
on non-serious adverse events. In addition to harms being seriously underreported, there is a lack of
long-term trials with a drug-free follow-up in both animal and human research.
It is very worrying that the large Multimodal Treatment Study (MTA) in children after 16 years of
follow-up reported that people who continued to take methylphenidate lost 5 cm in height compared
to those who only took a negligible amount of drug after the 14-months randomised phase was over
[46].
Clonidine is an antiadrenergic agent approved for treatment of hypertension in 1974 [47]. It is well
known that hypotensive agents can cause sexual dysfunction [48, 49]; to prescribe clonidine to children
and adolescents may have a similar negative impact.
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5.3. Implications
We consider it likely that the harms to the reproductive system seen in animals can also occur in
humans. This possibility should be studied in observational studies and also in the large MTA study.
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Appendix A: Searches
Searches were performed in PubMed, Biosis and Embase, using MeSH terms or the equivalent, for
drugs approved for ADHD symptoms (the eight most sold ADHD drugs as reported by the Food and
Drug Administration for 2012 [19] (atomoxetine, clonidine, dexmethylphenidate, dextroamphetamine,
guanfacine, lisdexamphetamine, methylphenidate and amphetamine)). We also went through the NTP-
CERHR report for eligible studies [18].
PubMed
Search ((“Reproductive Physiological Processes”[Mesh] OR “Reproduction“[Mesh])
AND (lisdexamfetamine OR “lisdexamfetamine dimesylate”[Supplementary Concept]
OR “Methylphenidate“[Mesh] OR “atomoxetine”[Supplementary Concept] OR “Guan-
facine“[Mesh] OR “Clonidine”[Mesh])) Filters: Other Animals
Result 140316 : 173
Embase
1 (dexamphetamine or atomoxetine or clonidine or guanfacine or methylphenidate or
lisdexamphetamine).mp. [mp = title, abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name, keyword]
69304
2 reproduct*.mp. [mp = title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword]
282123
3 (“non-human primate” or “nonhuman primate” or baboon or macaque or chimpanzee or
orangutan or “rhesus monkey” or “rhesus macaque” or marmoset or “cynomolgus monkey” or
gibbon or grivet or “squirrel monkey” or cat or dog or rodent or rat or mouse or rabbit or
guinea pig or hamster or gerbil).mp. [mp = title, abstract, heading word, drug trade name,
original title, device manufacturer, drug manufacturer, device trade name, keyword]
4087030
4 1 and 2 and 3 62
Search result 29 March 2016: 62 records
BIOSIS:
(from BIOSIS Previews)
You searched for: ((TOPIC: (((((((((((((((((((((“non-human primate” OR “nonhuman primate”) OR
baboon) OR macaque) OR chimpanzee) OR orangutan) OR “rhesus monkey”) OR “rhesus macaque”)
OR marmoset) OR “cynomolgus monkey”) OR gibbon) OR grivet) OR “squirrel monkey”) OR cat) OR
dog) OR rodent) OR rat) OR mouse) OR rabbit) OR guinea pig) OR hamster) OR gerbil) ANDTOPIC:
(reproduct*)) AND TITLE: ((((((((dexamphetamine OR atomoxetine) OR clonidine) OR guanfacine)
OR methylphenidate) OR lisdexamfetamine) OR dexmethylphenidate) OR dextroamphetamine) OR
amphetamine))
Timespan: All years. Indexes: BIOSIS Previews.
Results 29 March 2016: 335 records
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Appendix B: Protocol
Background
The MTA study was the ﬁrst and largest controlled trial aiming at assessing long-term outcomes
from use of ADHD drugs (1). However, the trial was not placebo-controlled or double-blinded (2).
There were no meaningful differences in outcomes after 14 months, three and eight years between
methylphenidate and patients receiving behavioural or community alternatives (3)(4)(5). Another
prospective study investigated overall functioning at six years follow-up and found that psychostimu-
lants had no beneﬁcial impact on ADHD symptom severity (6). In contrast, sustained effects were seen
with behavioural therapy (7).
Exposure to ADHDdrugs can impair sexual function (8) andmay possibly also impair the development
of the reproductive system. A case has been described where a boy experienced precocious puberty
with sexual hyperactivity and was diagnosed with familial male precocious puberty (9). He was treated
with methylphenidate from age ﬁve, which rapidly caused a decrease in aggression and hypersexuality
whereas other studies and case reports have shown increased sexual activity with methylphenidate
(9)(10), i.e. priapism from use of methylphenidate (11). Another case story is about a boy treated with
methylphenidate for 17 years since childhood and who experienced delayed puberty; at age 20 he had
underdeveloped genitalia, lack of libido and also erectile dysfunction (12).
A longitudinal study that investigated pubertal development in 65 boys on stimulant medication for at
least three years compared to 174 controls (13) found a slower rate of physical development during
puberty for medicated boys.
In pregnant mice, methylphenidate has been shown to cross the placenta and the drug was measurable
in the fetal brain at levels comparable to maternal plasma (14), which may affect the offspring’s
development. The percentage of offspring with cleft palate increased with increasing dose of clonidine
given to murine dams at day 11 of pregnancy (15).
It has been shown that methylphenidate administration to young rats, corresponding in age to prepu-
bertal children, resulted in altered levels of dopamine transporters that persisted into adulthood, long
after termination of treatment (16).
A large report from 2005 investigated the reproductive and developmental effects of methylphenidate
(17). There were no data on humans and for animals, the working group did not have sufﬁcient data
to give advice on reproduction, although they mentioned two studies demonstrating reduced sperm
motility and altered estrous cycling, respectively, and one study reporting no differences. A study in
rats found that methylphenidate impaired normal spermatogenesis after eleven weeks of treatment,
which indicated that the drug might reduce male reproductivity (18).
A review from 2006 of sexual maturation in children and adolescents included only two studies and
had no clear conclusion (19). We decided to do a systematic review of animal studies to study the
impact of ADHD drugs on the development of the reproductive organs.
Aim
To assess whether drugs approved for ADHD symptoms cause abnormal development of reproductive
organs in animals.
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Methods
Search strategy
Searches will be performed in PubMed, Biosis and Embase, using MeSH terms or the equivalent, for
drugs approved for ADHD symptoms (the eight most sold ADHD drugs as reported by the Food and
Drug Administration for 2012 (20) (atomoxetine, clonidine, dexmethylphenidate, dextroamphetamine,
guanfacine, lisdexamphetamine, methylphenidate and amphetamine)). We will also go through the
NTP-CERHR report for eligible studies (17).
We will contact authors for outcome data that are unclear or not reported in the papers published in
2006 or later, going back ten years.
Eligibility criteria and data extraction
We will include monotherapeutic, controlled studies on drugs for ADHD symptoms on healthy mam-
mals, i.e. they will not be castrated or ovariectomized or otherwise primed for behaviour resembling
ADHD symptoms. We will only investigate the changes in the reproductive organs of the animals; we
will include studies on outcomes related to the pregnancy period (miscarriages) and labour (animals
not able to give birth or number of stillborns).
We will extract data on outcomes like sizes of reproductive organs, motility, cell counts, morphology
and morphometrics, ability of ejaculation, estrous cycle, pregnancy, live births. Outcomes will be cate-
gorized as morphology incl. metrics, spermmotility, ejaculation, cell counts, cycles, pregnancy/labour.
We will not be investigating if the drugs cause changes in the offspring or whether the animals are
normally lactating, therefore only postnatal interventions are eligible. Interventionsmust be carried out
in live animals, thus we exclude in vitro studies. We will exclude human studies, methodological papers
and studies not having the reproductive system as an outcome category as well as pharmacological
or biochemical surrogate outcomes. Gender-speciﬁc data will not be lumped due to differences in
outcomes. Non-English articles will be excluded due to amount of resources.
If there are at least two eligible studies for an outcome, meta-analysis will be performed using the last
time point at the end of intervention. If there are several active groups (different drugs related to the
same control group), we will split the control group accordingly to avoid double counting.
One observer will screen all records and a second observer will screen a random sample of 15 excluded
records and all included records to check for inter-rater variability.
Potentially eligible articles will be collected and read in full. References of eligible articles will be
scanned to locate further studies. Data will be entered in Excel and in ReviewManager for analysis.
One investigator will be carrying out data extraction independently and a second investigator will be
controlling for validity of the extracted data. If disagreements, consensus will be reached, using a third
assessor if disagreement arises.
Quantitative data synthesis
We will extract data according to published guidelines (21)(22)(23)(24): animals (species, strain, age,
sex), study design (drug intervention, group size, dose, route of administration, housing condition,
treatment length and follow-up length), risk of bias (blinding, randomisation, selective reporting) and
relevant outcome measures.
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If several doses are included per study, they will be pooled per mean and standard deviation (25). If in
doubt, we will ask an arbiter who has not seen the data set. Animals kept group-housed or isolated will
be pooled. The total number of intervention groups after combining them will determine the splitting
of the control group. If similar tests are performed on consecutive days, results for the ﬁrst test day
will be reported.
As we do not expect medication for ADHD symptoms to cause better outcomes related to reproductive
parameters, outcomes will be transformed by multiplying with -1 when relevant.
We will perform sensitivity analyses with respect to choice of drug. Exploratory subgroup analyses
will be performed for rats only, blinded observers, age at intervention (young/adolescent, intervention
ended <PND56 vs adults, intervention ended >PND56), and a simple comparison of assessments at
end of intervention vs after a drug-free follow-up period.
Risk of bias is assessed according to the methods by Syrcle (21)(25). For animal studies, the Syrcle
risk of bias tool recommended assessment of three categories of randomisation, namely randomisation
of animals to intervention or control groups; random housing to prevent behavioural differences
between groups introduced through differences in light intensity and temperature; and randomoutcome
assessments to prevent inﬂuence on results from diurnal variation (21).
All results will be reported in relevant tables and text.
Statistical methods
We will use a random effects model. For binary data, risk ratios (RR) will be reported. For the meta-
analyses of continuous data and ranking scale data, the standardised mean difference is calculated or
the mean differences will be used.
Pooling of means and standard deviations is done as advised by the Cochrane Handbook (25).
Heterogeneity is assessed as I-square and further explored by subgroup and sensitivity analyses to
determine the impact of explanatory factors (23)(25)(26).
Missing standard deviations are calculated or estimated by standard methods (25), e.g. imputing from
SEs or p-values. If SD values are not estimable, results will not be used for meta-analysis.
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Appendix C: Literature search – ﬂow chart
Biosis
335 records
EMBASE
62 records
PubMed
173 records
Total
573 records
Total
518 records
Eligible records:
57 records
Removal of duplicate records:  
55 excluded
Screening of ?tles and abstracts:  
461 excluded
Addi?onal records*
3 records
Included in analysis:
27 records
Screening of full text records:
30 excluded for reasons: non-
English ar?cles, in vitro studies, 
wrong outcomes, primed animals, 
not controlled studies
Included in analysis, amended protocol:
17 records
Included in meta-analysis:
12 records
∗Additional records identified through “related papers” function and references of screened papers.
